中恆集團(600252.SH)受新版醫保目錄影響明年血栓通銷量或降15%-25%
格隆匯8月21日丨中恆集團(600252.SH)公佈，2019年8月20日，國家醫保局、人力資源社會保障部關於印發了《國家基本醫療保險、工傷保險和生育保險藥品目錄》的通知【醫保發〔2019〕46號】，正式公佈了國家基本醫療保險、工傷保險和生育保險藥品目錄。國家新版醫保目錄中成藥部分，本公司產品注射用血栓通(凍幹)、血栓通注射液均為甲類醫保，備註限二級及以上醫療機構的中風偏癱或視網膜中央靜脈阻塞的患者。
本次醫保目錄調整內容包含了公司的產品注射用血栓通(凍幹)、血栓通注射液，對公司效益將會帶來影響。2018年度，公司注射用血栓通(凍幹)、血栓通注射液的營業收入分別為29.81億元、0.16億元，佔中恆集團同期營業收入總額的90.38%、0.47%；毛利分別為28.09億元、0.11億元；產品毛利率分別為94.22%、71.40%。2019年度第一季度，公司注射用血栓通(凍幹)、血栓通注射液的營業收入分別為7.93億元、0.03億元，佔同期公司營業收入總額的90.58%、0.38%；毛利分別為7.53億元、0.02億元；毛利率分別為94.87%、70.61%。
目前注射用血栓通(凍幹)、血栓通注射液主要用於瘀血阻絡、中風偏癱、胸痺心痛及視網膜中央靜脈阻塞症，本次醫保目錄報銷範圍減去了瘀血阻絡、胸痺心痛兩個適應症。注射用血栓通(凍幹)、血栓通注射液均屬國家基本藥物，由於本次醫保目錄將於2020年1月1日正式實行，預計本年度對公司血栓通銷售影響較小，對照公司2018年銷售數據分析，預計2020年血栓通銷量將會下降15%-25%。
公司計劃進一步加強血栓通循證醫學研究，加快安全性、有效性的再評價工作，加強血栓通的基礎和臨牀研究，為臨牀使用提供支撐。完成血栓通標準化建設，不斷提升血栓通產品質量，保證臨牀用藥安全有效。加強學術推廣，提高醫生對血栓通的瞭解，提高臨牀使用的安全性。緊跟醫保目錄的調整，加強學術推廣，確保在中風偏癱、視網膜中央靜脈阻塞病症上佔據更多的市場份額。同時，公司正在加大中華跌打丸、炎見寧、婦炎淨等產品的銷售推廣力度，加大新藥研發力度，並通過併購豐富公司產品管線，減少對血栓通單品的依賴。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
